Context Therapeutics Invites Investors to Exciting Conferences
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a pioneering clinical-stage biopharmaceutical company, focuses on developing innovative T cell engaging bispecific antibodies targeting solid tumors. The Company is eager to participate in two significant upcoming investor conferences that promise to highlight its advancements and future potential in the oncology sector.
Details of Upcoming Investor Conferences
Context Therapeutics is thrilled to announce its involvement in the following key investor engagements:
Guggenheim 2nd Annual Healthcare Innovation Conference
This conference will take place from November 10-12 in Boston. Context is scheduled to participate in a fireside chat on Monday, November 10, at 3:00 PM ET. Additionally, the Company will hold 1x1 meetings on the same day, allowing for tailored discussions with attendees.
Stifel 2025 Healthcare Conference
Following the Guggenheim conference, Context Therapeutics will attend the Stifel 2025 Healthcare Conference from November 11-13 in New York. The Company will deliver a presentation on Wednesday, November 12, at 10:00 AM ET, along with 1x1 meetings held that day. This platform offers a unique opportunity for investors to engage directly with the management team.
Accessing Live Webcasts and Replays
For those interested in following Context Therapeutics' presentations, a live webcast will be made available via the Company's website in the News and Events section. Recordings will also be accessible for 90 days, ensuring that all interested parties can stay informed about the pivotal discussions and updates shared during these investor conferences.
About Context Therapeutics
Context Therapeutics Inc. (Nasdaq: CNTX) is committed to advancing T cell engaging (“TCE”) bispecific antibodies designed to treat solid tumors. The Company is significantly enhancing its portfolio with innovative therapeutics such as CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context operates from its headquarters in Philadelphia, focusing on ground-breaking research and development in oncology.
Get in Touch with Context Therapeutics
For additional inquiries or to arrange meetings with the management team during the aforementioned events, please reach out to your respective conference representative or contact the Company directly through their investor relations email.
Frequently Asked Questions
What is the purpose of the conferences Context Therapeutics is attending?
These conferences provide an excellent platform for Context Therapeutics to present its ongoing developments and engage directly with potential investors.
Who can attend the 1x1 meetings during the conferences?
Investors interested in discussing Context’s strategies and advancements can participate in the scheduled 1x1 meetings by contacting their conference representative.
Where can I find the live webcasts of Context's presentations?
The live webcasts will be available in the News and Events section of Context Therapeutics' website.
How long will the replays of the presentations be accessible?
Replays of the presentations will be available for 90 days on the Company's website after the events.
What advancements is Context Therapeutics focusing on?
Context Therapeutics focuses on developing innovative T cell engaging bispecific antibodies to address the challenges of solid tumors in the oncology space.